3-deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice

被引:77
作者
Bray, M [1 ]
Raymond, JL
Geisbert, T
Baker, RO
机构
[1] USA, Med Res Inst Infect Dis, Div Virol, Dept Viral Therapeut, Frederick, MD 21702 USA
[2] USA, Med Res Inst Infect Dis, Div Pathol, Frederick, MD 21702 USA
关键词
Ebola virus; filovirus; antiviral therapy; S-adenosyl-L-homocysteine hydrolase; interferon-alpha;
D O I
10.1016/S0166-3542(02)00018-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
3-Deazaneplanocin A, an analog of adenosine, is a potent inhibitor of Ebola virus replication. A single dose early in infection prevents illness and death in Ebola virus-infected mice. The ability of this and similar compounds to block both RNA and DNA viruses has been attributed to the inhibition of a cellular enzyme, S-adenosylhomocysteine hydrolase (SAH), indirectly resulting in reduced methylation of the 5' cap of viral messenger RNA. However, we found that the protective effect of the drug resulted from massively increased production of interferon-alpha in Ebola-infected, but not uninfected mice. Peak interferon levels increased with the extent of disease at the time of treatment, indicating that production was boosted only in virus-infected cells. Ebola virus has been shown to suppress innate antiviral mechanisms of the type I interferon response. 3-Deazaneplanocin A appears to reverse such suppression, restricting viral dissemination. Further development should focus on identifying adenosine analogues that produce a similar effect in Ebola virus-infected primates. Published by Elsevier Science B.V.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 28 条
[1]   The Ebola virus VP35 protein functions as a type IIFN antagonist [J].
Basler, CF ;
Wang, XY ;
Mühlberger, E ;
Volchkov, V ;
Paragas, J ;
Klenk, HD ;
Garcia-Sastre, A ;
Palese, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) :12289-12294
[2]   A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever [J].
Bray, M ;
Davis, K ;
Geisbert, T ;
Schmaljohn, C ;
Huggins, J .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (03) :651-661
[3]   Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus [J].
Bray, M ;
Hatfill, S ;
Hensley, L ;
Huggins, JW .
JOURNAL OF COMPARATIVE PATHOLOGY, 2001, 125 (04) :243-253
[4]   Experimental therapy of filovirus infections [J].
Bray, M ;
Paragas, J .
ANTIVIRAL RESEARCH, 2002, 54 (01) :1-17
[5]   The role of the Type I interferon response in the resistance of mice to filovirus infection [J].
Bray, M .
JOURNAL OF GENERAL VIROLOGY, 2001, 82 :1365-1373
[6]   Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor [J].
Bray, M ;
Driscoll, J ;
Huggins, JW .
ANTIVIRAL RESEARCH, 2000, 45 (02) :135-147
[7]  
Bray Mike, 2002, P875
[8]   INFLUENCE OF S-ADENOSYLHOMOCYSTEINE HYDROLASE INHIBITORS ON S-ADENOSYLHOMOCYSTEINE AND S-ADENOSYLMETHIONINE POOL LEVELS IN L929 CELLS [J].
COOLS, M ;
DECLERCQ, E .
BIOCHEMICAL PHARMACOLOGY, 1990, 40 (10) :2259-2264
[9]   PHARMACOKINETICS OF THE ANTIVIRAL AGENT 3-DEAZANEPLANOCIN-A [J].
COULOMBE, RA ;
SHARMA, RP ;
HUGGINS, JW .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1995, 20 (03) :197-202
[10]   Carbocyclic adenosine analogues as S-adenosylhomocysteine hydrolase inhibitors and antiviral agents: Recent advances [J].
De Clercq, E .
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 1998, 17 (1-3) :625-634